In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA

BackgroundProstate-specific membrane antigen (PSMA) targeting radioligands have transformed treatment of prostate cancer. Radioligand therapy (RLT) with 177Lu-PSMA in metastasized castration resistant prostate cancer (mCRPC) achieves objective response and disease stabilization in roughly two third...

Full description

Bibliographic Details
Main Authors: Vikas Prasad, Kai Huang, Sonal Prasad, Marcus R. Makowski, Norbert Czech, Winfried Brenner
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
radioligand therapy
Lu-177-PSMA
interim staging
Ga-68-PSMA PET/CT
PSA response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.578093/full

Similar Items

Similar Items